Icatibant Sandoz (Icatibant)

Icatibant is used to manage hereditary angioedema, a disorder driven by excessive bradykinin activity.

• Acute hereditary angioedema (C1‑inhibitor deficiency): rapidly reduces swelling during attacks.
• Hereditary angioedema type I: provides quick symptom relief and improves airway safety.
• Hereditary angioedema type II: alleviates abdominal pain and facial swelling associated with attacks.

• Icatibant selectively blocks the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin‑induced vasodilation and increased vascular permeability. By inhibiting this pathway, it curtails the fluid extravasation that causes the swelling characteristic of hereditary angioedema attacks.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects

• Injection site pain: discomfort at the site of subcutaneous administration.
• Injection site erythema: redness around the injection area.
• Nausea: feeling of sickness or urge to vomit.
• Headache: mild to moderate head pain.
• Dizziness: sensation of light‑headedness.
• Flushing: transient redness of the skin.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe hypotension: marked drop in blood pressure.
• Angioedema: swelling of deeper skin layers, potentially affecting the airway.
• Urticaria: hives or itchy welts.
• Severe injection site reactions: necrosis or extensive swelling.
• Thrombocytopenia: low platelet count observed rarely.

Before prescribing Icatibant, clinicians should consider several safety measures.

• Confirm diagnosis: ensure the patient has hereditary angioedema with C1‑inhibitor deficiency.
• Monitor hypersensitivity: watch for signs of anaphylaxis or severe allergic reactions.
• Contraindication check: avoid use in patients with known hypersensitivity to icatibant or its excipients.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Injection technique: do not administer multiple injections at the same site to reduce local tissue damage.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or affect injection site tolerance.

Major Interactions (Avoid)

• ACE inhibitors: may increase bradykinin levels and raise the risk of angioedema.
• Estrogen‑containing contraceptives: can exacerbate hereditary angioedema symptoms.
• Other bradykinin B2 antagonists: additive pharmacologic effect may increase adverse events.

Moderate Interactions (Monitor Closely)

• C1‑inhibitor concentrate: concurrent use may complicate assessment of therapeutic response.
• NSAIDs: may heighten the likelihood of local injection site reactions.